vs
Golden Matrix Group, Inc.（GMGI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Golden Matrix Group, Inc.的季度营收约是REGENXBIO Inc.的1.6倍（$49.6M vs $30.3M），Golden Matrix Group, Inc.净利率更高（-179.0% vs -221.3%，领先42.4%），REGENXBIO Inc.同比增速更快（43.0% vs -15.8%），Golden Matrix Group, Inc.自由现金流更多（$6.4M vs $-52.8M），过去两年Golden Matrix Group, Inc.的营收复合增速更高（104.6% vs 39.4%）
Golden Matrix Group Inc.是一家全球化游戏科技企业，开发并授权专属线上游戏平台、社交棋牌产品及互动游戏解决方案，服务覆盖北美、欧洲、亚太地区的B2B客户，同时运营面向普通用户的休闲游戏产品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GMGI vs RGNX — 直观对比
营收规模更大
GMGI
是对方的1.6倍
$30.3M
营收增速更快
RGNX
高出58.8%
-15.8%
净利率更高
GMGI
高出42.4%
-221.3%
自由现金流更多
GMGI
多$59.2M
$-52.8M
两年增速更快
GMGI
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $49.6M | $30.3M |
| 净利润 | $-88.7M | $-67.1M |
| 毛利率 | 57.5% | — |
| 营业利润率 | -188.3% | -190.0% |
| 净利率 | -179.0% | -221.3% |
| 营收同比 | -15.8% | 43.0% |
| 净利润同比 | -4880.1% | -31.2% |
| 每股收益（稀释后） | $-7.73 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMGIRGNX
| Q4 25 | $49.6M | $30.3M | ||
| Q3 25 | $47.3M | $29.7M | ||
| Q2 25 | $43.2M | $21.4M | ||
| Q1 25 | $42.7M | $89.0M | ||
| Q4 24 | $58.9M | $21.2M | ||
| Q3 24 | $41.0M | $24.2M | ||
| Q2 24 | $39.4M | $22.3M | ||
| Q1 24 | $11.8M | $15.6M |
净利润GMGIRGNX
| Q4 25 | $-88.7M | $-67.1M | ||
| Q3 25 | $566.0K | $-61.9M | ||
| Q2 25 | $-3.6M | $-70.9M | ||
| Q1 25 | $-231.6K | $6.1M | ||
| Q4 24 | $1.9M | $-51.2M | ||
| Q3 24 | $-3.4M | $-59.6M | ||
| Q2 24 | $64.9K | $-53.0M | ||
| Q1 24 | $74.5K | $-63.3M |
毛利率GMGIRGNX
| Q4 25 | 57.5% | — | ||
| Q3 25 | 55.8% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.6% | — | ||
| Q4 24 | 69.8% | 70.2% | ||
| Q3 24 | 54.7% | 48.8% | ||
| Q2 24 | 55.0% | 52.5% | ||
| Q1 24 | 28.5% | 72.6% |
营业利润率GMGIRGNX
| Q4 25 | -188.3% | -190.0% | ||
| Q3 25 | -0.8% | -176.3% | ||
| Q2 25 | -5.3% | -296.3% | ||
| Q1 25 | -0.2% | 13.6% | ||
| Q4 24 | 5.6% | -242.1% | ||
| Q3 24 | -2.4% | -256.6% | ||
| Q2 24 | 0.3% | -251.3% | ||
| Q1 24 | 2.4% | -408.8% |
净利率GMGIRGNX
| Q4 25 | -179.0% | -221.3% | ||
| Q3 25 | 1.2% | -208.3% | ||
| Q2 25 | -8.3% | -331.8% | ||
| Q1 25 | -0.5% | 6.8% | ||
| Q4 24 | 3.2% | -241.3% | ||
| Q3 24 | -8.3% | -246.3% | ||
| Q2 24 | 0.2% | -237.7% | ||
| Q1 24 | 0.6% | -405.4% |
每股收益（稀释后）GMGIRGNX
| Q4 25 | $-7.73 | $-1.30 | ||
| Q3 25 | $0.00 | $-1.20 | ||
| Q2 25 | $-0.03 | $-1.38 | ||
| Q1 25 | $0.00 | $0.12 | ||
| Q4 24 | $-0.13 | $-0.99 | ||
| Q3 24 | $-0.03 | $-1.17 | ||
| Q2 24 | $0.00 | $-1.05 | ||
| Q1 24 | $0.00 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $46.5M | $102.7M |
| 总资产 | $118.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMGIRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益GMGIRGNX
| Q4 25 | $46.5M | $102.7M | ||
| Q3 25 | $123.5M | $161.5M | ||
| Q2 25 | $121.3M | $213.7M | ||
| Q1 25 | $108.5M | $274.2M | ||
| Q4 24 | $105.1M | $259.7M | ||
| Q3 24 | $94.3M | $301.4M | ||
| Q2 24 | $90.4M | $348.3M | ||
| Q1 24 | $32.1M | $390.7M |
总资产GMGIRGNX
| Q4 25 | $118.1M | $453.0M | ||
| Q3 25 | $209.8M | $525.2M | ||
| Q2 25 | $210.3M | $581.0M | ||
| Q1 25 | $214.0M | $490.9M | ||
| Q4 24 | $213.7M | $466.0M | ||
| Q3 24 | $213.5M | $519.1M | ||
| Q2 24 | $191.5M | $569.4M | ||
| Q1 24 | $37.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $6.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 13.0% | -174.0% |
| 资本支出强度资本支出/营收 | 3.6% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $19.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GMGIRGNX
| Q4 25 | $8.2M | $-52.3M | ||
| Q3 25 | $7.0M | $-56.0M | ||
| Q2 25 | $2.4M | $-49.3M | ||
| Q1 25 | $7.7M | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $4.8M | $-40.5M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | $8.2K | $-55.5M |
自由现金流GMGIRGNX
| Q4 25 | $6.4M | $-52.8M | ||
| Q3 25 | $6.2M | $-56.5M | ||
| Q2 25 | $-89.4K | $-49.7M | ||
| Q1 25 | $6.6M | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | $2.3M | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | $6.7K | $-56.0M |
自由现金流率GMGIRGNX
| Q4 25 | 13.0% | -174.0% | ||
| Q3 25 | 13.1% | -189.9% | ||
| Q2 25 | -0.2% | -232.8% | ||
| Q1 25 | 15.5% | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | 5.6% | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | 0.1% | -358.5% |
资本支出强度GMGIRGNX
| Q4 25 | 3.6% | 1.7% | ||
| Q3 25 | 1.8% | 1.7% | ||
| Q2 25 | 5.7% | 1.8% | ||
| Q1 25 | 2.6% | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 6.0% | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率GMGIRGNX
| Q4 25 | — | — | ||
| Q3 25 | 12.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMGI
| R Kings And CFAC | $43.8M | 88% |
| Other | $5.8M | 12% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
